Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck Kgaa ADR (MKKGY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.0370 +0.68%
on 04/18/19
23.1300 -8.43%
on 04/08/19
-1.0350 (-4.66%)
since 03/22/19
3-Month
20.4200 +3.72%
on 01/24/19
23.1300 -8.43%
on 04/08/19
+0.6900 (+3.37%)
since 01/22/19
52-Week
18.8600 +12.30%
on 05/15/18
23.1300 -8.43%
on 04/08/19
+0.8600 (+4.23%)
since 04/20/18

Most Recent Stories

More News
Global Microbial Identification Market Report 2019-2023 with Market Positioning of Key Vendors - Charles River, Danaher, Merck KGaA, QIAGEN, & Thermo Fisher Scientific

The "Global Microbial Identification Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

MKKGY : 21.1800 (+0.19%)
Merck KGaA, Darmstadt, Germany, Signs Definitive Agreement to Acquire Versum Materials for $53 per Share

--Versum is a "Best in Class" asset with industry-leading financial metrics

VSM : 51.99 (-0.02%)
APD : 196.62 (-0.75%)
MKKGY : 21.1800 (+0.19%)
Sonde Completes $16 Million Series A Financing Round to Advance Vocal Biomarker Technology

Sonde Health Inc., a company developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, today announced the completion of a...

MTZPY : 13.2250 (+0.27%)
MKKGY : 21.1800 (+0.19%)
Preferential First-Line Use of Biogen's Tecfidera and Continued Uptake of Merck KGaA's Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year

Self-reported oral disease-modifying therapy (DMT) class share has increased significantly over the past year in the EU multiple sclerosis (MS) market, pulling share from the injectable DMT classes. In...

NVS : 75.40 (-1.32%)
MKKGY : 21.1800 (+0.19%)
Versum Materials Receives Revised Proposal from Merck KGaA; Board Determines Revised Offer Constitutes a "Superior Proposal" to Entegris Transaction

Versum Materials, Inc. (NYSE: VSM) today announced that it has received a revised proposal from Merck KGaA, Darmstadt, Germany ("Merck") to acquire Versum for $53 per share, and that Versum's...

VSM : 51.99 (-0.02%)
APD : 196.62 (-0.75%)
MRK : 73.46 (+0.37%)
ENTG : 40.69 (+0.20%)
MKKGY : 21.1800 (+0.19%)
Elmar Schnee and Diane Parks Proposed as New Board Members of Calliditas Therapeutics

The nomination committee of Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) ("Calliditas") has proposed that Elmar Schnee and Diane Parks be elected as new Board members at the company's Annual General...

MRK : 73.46 (+0.37%)
MKKGY : 21.1800 (+0.19%)
The Healthcare Business of Merck KGaA, Darmstadt, Germany Standardizes on Veeva CRM Globally to Improve Commercial Execution Across Channels

Veeva Systems (NYSE:VEEV) today announced that the Healthcare business of Merck KGaA, Darmstadt, Germany has selected Veeva CRM to improve operating efficiency and commercial effectiveness...

VEEV : 134.06 (+4.87%)
MKKGY : 21.1800 (+0.19%)
EvoNexus Technology Incubator in Partnership with EMD Performance Materials is Accepting Applications to Admit New Startups

EvoNexus, Southern California's leading startup incubator with locations in San Diego and Irvine, in partnership with EMD Performance Materials, the North America high-tech materials business...

MKKGY : 21.1800 (+0.19%)
Analytical Standards Market to Expand at a Steady 6.30% CAGR during 2017-2022, with Availability of Government Expenditures - TMR

The global analytical standards market is considerably in competition and fragmented, says Transparency Market Research dependent on a recently issued report. This is because of the presence of a large...

A : 75.57 (-0.79%)
MKKGY : 21.1800 (+0.19%)
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved MAVENCLAD® (cladribine)...

MKKGY : 21.1800 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MKKGY with:

Key Turning Points

2nd Resistance Point 21.3267
1st Resistance Point 21.2533
Last Price 21.1800
1st Support Level 21.0833
2nd Support Level 20.9867

See More

52-Week High 23.1300
Fibonacci 61.8% 21.4989
Last Price 21.1800
Fibonacci 50% 20.9950
Fibonacci 38.2% 20.4911
52-Week Low 18.8600

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar